Pengaruh Fitokimia Resveratrol terhadap Penurunan Kadar HbA1c pada Pasien Diabetes Melitus Tipe 2 (DMT2): Tinjauan Literatur

Riska Fitriani; Dominikus Raditya Atmaka

doi:10.62027/vitamedica.v3i3.398

Authors

Riska Fitriani Universitas Airlangga
Dominikus Raditya Atmaka Universitas Airlangga

DOI:

https://doi.org/10.62027/vitamedica.v3i3.398

Keywords:

resveratrol, T2DM, RCT, supplementation

Abstract

Type 2 diabetes mellitus is a degenerative disease characterized by increased blood sugar levels due to insulin resistance. Many studies have examined the synergistic effect of nutraceutical supplementation to increase the effectiveness of drug therapy, one of which is resveratrol. However, studies that identify the effect of resveratrol on reducing HbA1c levels in patients with type 2 diabetes mellitus still have many inconsistencies in the reported results. The significance of these effects is based on the dose and timing of the particular intervention. Therefore, a literature review of several studies was carried out to assess the impact of resveratrol in treating type 2 diabetes mellitus through the HbA1c parameter and to explain the appropriate dose and duration of intervention. Articles included in the inclusion criteria are available in English and published within the last 10 years (2014-2024) in electronic databases such as PubMed-Medline, ScienceDirect, and SpringerLink. A literature review was conducted on experimental studies with type 2 diabetes patient subjects. The results of the literature review show that the recommended dose and duration that have the greatest significance in reducing HbA1c are at a dose of 200–500 mg/day for 6 months or >500 mg/day within 3 months. These results provide evidence that the adjusted dose and duration of resveratrol supplementation are very beneficial for the management of patients with type 2 diabetes mellitus.

References

Abdollahi, S., Salehi‐Abargouei, A., Toupchian, O., Sheikhha, M. H., Fallahzadeh, H., Rahmanian, M., ... & Mozaffari‐Khosravi, H. (2019). The effect of resveratrol supplementation on cardio‐metabolic risk factors in patients with type 2 diabetes: A randomized, double‐blind controlled trial. Phytotherapy Research, 33(12), 3153–3162.

Bain, S. C., Feher, M., Russell‐Jones, D., & Khunti, K. (2016). Management of type 2 diabetes: The current situation and key opportunities to improve care in the UK. Diabetes, Obesity and Metabolism, 18(12), 1157–1166.

Cao, M. M., Lu, X., Liu, G. D., Su, Y., Li, Y. B., & Zhou, J. (2018). Resveratrol attenuates type 2 diabetes mellitus by mediating mitochondrial biogenesis and lipid metabolism via Sirtuin type 1. Experimental and Therapeutic Medicine, 15(1), 576–584.

Chen, S., Zhao, Z., Ke, L., Li, Z., Li, W., Zhang, Z., ... & Zhu, W. (2018). Resveratrol improves glucose uptake in insulin-resistant adipocytes via Sirt1. The Journal of Nutritional Biochemistry, 55, 209–218.

Choudhari, V. P., Gore, K. P., & Pawar, A. T. (2017). Antidiabetic, antihyperlipidemic activities and herb–drug interaction of a polyherbal formulation in streptozotocin-induced diabetic rats. Journal of Ayurveda and Integrative Medicine, 8(4), 218–225.

Delgado, A. M., Issaoui, M., & Chammem, N. (2019). Analysis of main and healthy phenolic compounds in foods. Journal of AOAC International, 102(5), 1356–1364.

Ghadiri Soufi, F., Arbabi‐Aval, E., Rezaei Kanavi, M., & Ahmadieh, H. (2015). Anti‐inflammatory properties of resveratrol in the retinas of type 2 diabetic rats. Clinical and Experimental Pharmacology and Physiology, 42(1), 63–68.

Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014). Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Research and Clinical Practice, 103(2), 137–149.

Gupta, R. C., Chang, D., Nammi, S., Bensoussan, A., Bilinski, K., & Roufogalis, B. D. (2017). Interactions between antidiabetic drugs and herbs: An overview of mechanisms of action and clinical implications. Diabetology & Metabolic Syndrome, 9, 1–12.

He, L., Wang, H., Gu, C., He, X., Zhao, L., & Tong, X. (2016). Administration of traditional Chinese blood circulation activating drugs for microvascular complications in patients with type 2 diabetes mellitus. Journal of Diabetes Research, 2016, 1081657.

Hoca, M., Becer, E., & Vatansever, H. S. (2023). The role of resveratrol in diabetes and obesity associated with insulin resistance. Archives of Physiology and Biochemistry, 129(2), 555–561.

Imamura, H., Yamaguchi, T., Nagayama, D., Saiki, A., Shirai, K., & Tatsuno, I. (2017). Resveratrol ameliorates arterial stiffness assessed by cardio-ankle vascular index in patients with type 2 diabetes mellitus. International Heart Journal, 58(4), 577–583.

International Diabetes Federation (IDF). (2017). IDF diabetes atlas (8th ed.). https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf

Kemper, C., Behnam, D., Brothers, S., Wahlestedt, C., Volmar, C. H., Bennett, D., & Hayward, M. (2022). Safety and pharmacokinetics of a highly bioavailable resveratrol preparation (JOTROL™). AAPS Open, 8(1), 11.

Khodabandehloo, H., Seyyedebrahimi, S., Esfahani, E. N., Razi, F., & Meshkani, R. (2018). Resveratrol supplementation decreases blood glucose without changing the circulating CD14+ CD16+ monocytes and inflammatory cytokines in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Nutrition Research, 54, 40–51.

Mahjabeen, W., Khan, D. A., & Mirza, S. A. (2022). Role of resveratrol supplementation in regulation of glucose homeostasis, inflammation, and oxidative stress in patients with diabetes mellitus type 2: A randomized, placebo-controlled trial. Complementary Therapies in Medicine, 66, 102819.

Mezil, S. A., & Abed, B. A. (2021). Complication of diabetes mellitus. Annals of the Romanian Society for Cell Biology, 1546–1556.

Movahed, A., Nabipour, I., Louis, X. L., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., ... & Netticadan, T. (2013). Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evidence-Based Complementary and Alternative Medicine, 2013.

Seyyedebrahimi, S., Khodabandehloo, H., Nasli Esfahani, E., & Meshkani, R. (2018). The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled clinical trial. Acta Diabetologica, 55, 341–353.

Sherwani, S. I., Khan, H. A., Ekhzaimy, A., Masood, A., & Sakharkar, M. K. (2016). Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomarker Insights, 11, BMI-S38440.

Sin, T. K., Yung, B. Y., & Siu, P. M. (2015). Modulation of SIRT1-Foxo1 signaling axis by resveratrol: Implications in skeletal muscle aging and insulin resistance. Cellular Physiology and Biochemistry, 35(2), 541–552.

Su, M., Zhao, W., Xu, S., & Weng, J. (2022). Resveratrol in treating diabetes and its cardiovascular complications: A review of its mechanisms of action. Antioxidants, 11(6), 1085.

Timmers, S., De Ligt, M., Phielix, E., Van De Weijer, T., Hansen, J., Moonen-Kornips, E., ... & Schrauwen, P. (2016). Resveratrol as add-on therapy in subjects with well-controlled type 2 diabetes: A randomized controlled trial. Diabetes Care, 39(12), 2211–2217.

Tomita, T. (2016). Apoptosis in pancreatic β-islet cells in type 2 diabetes. Bosnian Journal of Basic Medical Sciences, 16(3), 162.

Wang, P., & Sang, S. (2018). Metabolism and pharmacokinetics of resveratrol and pterostilbene. Biofactors, 44(1), 16–25.

Xie, W., & Du, L. (2011). Diabetes is an inflammatory disease: Evidence from traditional Chinese medicines. Diabetes, Obesity and Metabolism, 13(4), 289–301.

Yonamine, C. Y., Pinheiro-Machado, E., Michalani, M. L., Freitas, H. S., Okamoto, M. M., Corrêa-Giannella, M. L., & Machado, U. F. (2016). Resveratrol improves glycemic control in insulin-treated diabetic rats: Participation of the hepatic territory. Nutrition & Metabolism, 13, 1–10.